Table 1 Pilot CRCT Demographic data
Medical Wards Phase | Online Learning Ward | PB | Face to Face (F2F) Ward | PF | Control Ward | PC | Pbaseline | |||
|---|---|---|---|---|---|---|---|---|---|---|
Baseline + Rollout | Post intervention | Baseline + Rollout | Post intervention | Baseline + Rollout | Post intervention | |||||
Number of patients (n) | 151 | 213 | 96 | 107 | 123 | 137 | ||||
Age in years | 69.8 (± 12.7) | 68.4 (± 11.2) | 0.446 | 68.2 (± 12.0) | 67.1 (± 11.2) | 0.773 | 70.9 (± 13.2) | 69.9 (± 13.7) | 0.581 | 0.098 |
Gender (Female) | 56(37%) | 88(41%) | 0.330 | 54(56%) | 49(46%) | 0.078 | 69(56%) | 65(47%) | 0.325 | 0.968 |
European Descent | 115(76%) | 143(67%) | 0.062 | 75(78%) | 81(76%) | 0.818 | 92(75%) | 100(73%) | 0.893 | 0.471 |
Diabetes Type | ||||||||||
Type 1 (%) | 4(3%) | 11(5%) | 0.182 | 3(3%) | 7(7%) | 0.295 | 8(7%) | 4(3%) | 0.259 | 0.232 |
Type 2 (%) | 147(97%) | 202(95%) | 93(97%) | 99(93%) | 115(93%) | 133(97%) | ||||
Glucose on admission (mmol/L) | 12.5(± 5.3) | 13.0(± 5.1) | 0.494 | 13.9(± 7.0) | 12.6(± 5.1) | 0.200 | 13.4(± 6.1) | 13.3(± 5.3) | 0.900 | 0.734 |
Type of admission | ||||||||||
Emergency | 141(93%) | 196(92%) | 0.011 | 90(94%) | 95(89%) | 0.414 | 121(98%) | 132(96%) | 0.071 | 0.488 |
Elective | 1(1%) | 12(6%) | 1(1%) | 2(2%) | 0(0%) | 3(2%) | ||||
Transfer | 9(6%) | 5(2%) | 5(5%) | 10(9%) | 2(2%) | 2(1%) | ||||
Treatment on Admission | ||||||||||
Lifestyle | 18(12%) | 9(4%) | 0.012 | 11(11%) | 9(8%) | 0.244 | 13(11%) | 18(13%) | 0.189 | 0.690 |
Tablet | 86(57%) | 128(60%) | 45(47%) | 66(62%) | 58(47%) | 75(55%) | ||||
Insulin | 39(26%) | 66(31%) | 30(31%) | 25(23%) | 32(26%) | 37(27%) | ||||
GLP 1 | 0(0%) | 4(2%) | 0(0%) | 3(3%) | 0(0%) | 3(2%) | ||||
Insulin treated T2DM (%) | 35(23%) | 55(26%) | 0.319 | 27(28%) | 18(17%) | 0.074 | 24(20%) | 33(24%) | 0.561 | 0.428 |
Total patients with BGL > 11 mmol/L | 70(46%) | 124(58%) | < 0.001 | 56(58%) | 60(56%) | 0.792 | 69(56%) | 82(60%) | 0.703 | 0.814 |
Admission reason | ||||||||||
Diabetes | 3(2%) | 3(1%) | 0.976 | 6(6%) | 1(1%) | 0.044 | 12(10%) | 6(4%) | 0.110 | 0.014 |
Other | 147(97%) | 210(99%) | 90(94%) | 106(99%) | 111(90%) | 131(96%) | ||||
Documented Complications present | ||||||||||
Chronic kidney disease | 9(6%) | 18(8%) | 0.382 | 2(2%) | 2(2%) | 0.944 | 9(7%) | 13(9%) | 0.334 | 0.228 |
Foot disease | 5(3%) | 8(4%) | 0.830 | 2(2%) | 4(4%) | 0.457 | 7(6%) | 7(5%) | 0.624 | 0.308 |
Macrovascular | 22(15%) | 64(30%) | < 0.0001 | 13(14%) | 20(19%) | 0.779 | 15(12%) | 18(13%) | 0.349 | 0.641 |
Autonomic | 3(2%) | 13(6%) | 0.132 | 3(3%) | 4(4%) | 0.770 | 3(2%) | 7(5%) | 0.960 | 0.832 |
Eye disease | 3(2%) | 9(4%) | 0.481 | 1(1%) | 2(2%) | 0.602 | 2(2%) | 6(4%) | 0.139 | 0.641 |